Policy Cures Research has developed this tracker to help funders, policy makers, researchers and others understand the evolving landscape of R&D for COVID-19. The dashboards below track funding commitments for basic research and product development R&D, and the current status and makeup of the pipeline of new drugs, vaccines and diagnostics, allowing users to identify the key financial and scientific contributors to the global fight against COVID-19.
The dashboards are best viewed in full screen mode, using the buttons at the bottom right of the visualisations.
For a detailed explanation of the scope of this tracking effort and some of the important methodological decisions we’ve made, please see the ‘Why is Policy Cures Research doing this?’ and ‘Types of funding announcements included’ sections at the bottom of the page.
All of the funding and pipeline data behind this dashboard has been reviewed and validated, but we are relying on publicly available information in a rapidly evolving situation, and as such we acknowledge that our data will never be completely comprehensive. If you identify any errors or omissions please contact us at firstname.lastname@example.org.
This dashboard provides an overview of the global pipeline of potential new vaccines, therapeutics and diagnostics currently under investigation for COVID-19. The interactive sunburst on the left is linked to the table below, allowing stratification by product type, technology, target and R&D stage. Use the developer search box on the right to search by organisation.
It is important to note that our tracking approach is to count only unique candidates and combinations; while it’s useful to understand how many organisations are investigating hydroxychloroquine, the fact that the same drug is being investigated in multiple trials shouldn’t be confused with a diverse R&D pipeline.
This dashboard provides an overview of global funding commitments for COVID-19 R&D since 1 January 2020. The tree map on the left provides a breakdown of announced funding by product type, and is linked to the table below. Funding can be filtered by funder and/or recipient using the dropdowns on the right, by country (by selecting countries on the map), or by product.
In addition to funding which is provided directly to product developers by funders (the ‘Primary funding’ checkbox on the right), it is also possible to analyse funding to intermediaries (such as CEPI) and the onward funding provided by intermediaries to product developers, using the relevant checkboxes. Since funding to intermediaries and onward funding represent different parts of the same funding flow, showing both simultaneously would result in double counting and is therefore discouraged.
The full text of the funding announcements set out in the table can be accessed via the links in the ‘Announcement text’ column.
The totals above do not include all of the €7.4 billion pledged by world leaders as part of the European Commission-coordinated Coronavirus Global Response fundraising event on 4 May 2020. Some of the funding in these pledges had already been captured in the tracker, and some is outside its scope (such as for procurement and distribution of newly-developed tools). Pledged funding that was clearly additional and in scope has been included in our 5 May update, and all pledges will be evaluated for inclusion as more details are made available. (More…)
We believe that these are acceptable compromises in order to provide users with actionable data now, rather than after the pandemic has been defeated, but remain committed to the G-FINDER methodology as the best tool for the long-term monitoring of R&D funding.